OBJECTIVE: To determine the exercise capacity of children and adolescents with Friedreich's Ataxia (FA) and to evaluate the effects of 6 months of idebenone treatment on exercise capacity. DESIGN: Exploratory endpoint in a randomized double-blind, placebo-controlled, phase II clinical trial designed to investigate the effects of idebenone on a biomarker of oxidative stress. SETTING: Exercise physiology laboratory in a single clinical research center. PARTICIPANTS: Ambulatory subjects (N=48; age range, 9-17 y) with genetically confirmed FA. INTERVENTION: Idebenone administered orally 3 times a day for a total daily dose of approximately 5, 15, and 45 mg/kg or matching placebo for 6 months. MAIN OUTCOME MEASURES: Peak oxygen consumption per unit time (peak VO(2)) and peak work rate (WR) were measured during incremental exercise testing at baseline and after treatment. Echocardiography and neurologic assessments were also completed before and after treatment. RESULTS:Baseline mean peak VO(2) +/- SD was 746+/-246 mL/min (16.2+/-5.8 mL/kg/min), and WR was 40+/-23 W for all subjects. Peak VO(2) and WR were correlated with short guanine-adenine-adenine allele length and neurologic function. Relative left ventricular wall thickness was increased but left ventricular ejection fraction was normal in most subjects; there was no relationship between any exercise and echocardiographic measures. There were no significant changes in mean peak VO(2) or WR after idebenone treatment at any dose level relative to placebo. CONCLUSIONS:Exercise capacity in children and adolescents with FA was significantly impaired. The basis for the impairment appears to be multifactorial and correlated to the degree of neurologic impairment. Although idebenone has previously been shown potentially to improve features of FA, idebenone treatment did not increase exercise capacity relative to placebo. Copyright2010 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.
RCT Entities:
OBJECTIVE: To determine the exercise capacity of children and adolescents with Friedreich's Ataxia (FA) and to evaluate the effects of 6 months of idebenone treatment on exercise capacity. DESIGN: Exploratory endpoint in a randomized double-blind, placebo-controlled, phase II clinical trial designed to investigate the effects of idebenone on a biomarker of oxidative stress. SETTING: Exercise physiology laboratory in a single clinical research center. PARTICIPANTS: Ambulatory subjects (N=48; age range, 9-17 y) with genetically confirmed FA. INTERVENTION: Idebenone administered orally 3 times a day for a total daily dose of approximately 5, 15, and 45 mg/kg or matching placebo for 6 months. MAIN OUTCOME MEASURES: Peak oxygen consumption per unit time (peak VO(2)) and peak work rate (WR) were measured during incremental exercise testing at baseline and after treatment. Echocardiography and neurologic assessments were also completed before and after treatment. RESULTS: Baseline mean peak VO(2) +/- SD was 746+/-246 mL/min (16.2+/-5.8 mL/kg/min), and WR was 40+/-23 W for all subjects. Peak VO(2) and WR were correlated with short guanine-adenine-adenine allele length and neurologic function. Relative left ventricular wall thickness was increased but left ventricular ejection fraction was normal in most subjects; there was no relationship between any exercise and echocardiographic measures. There were no significant changes in mean peak VO(2) or WR after idebenone treatment at any dose level relative to placebo. CONCLUSIONS: Exercise capacity in children and adolescents with FA was significantly impaired. The basis for the impairment appears to be multifactorial and correlated to the degree of neurologic impairment. Although idebenone has previously been shown potentially to improve features of FA, idebenone treatment did not increase exercise capacity relative to placebo. Copyright 2010 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.
Authors: A Charloux; E Lonsdorfer-Wolf; R Richard; E Lampert; M Oswald-Mammosser; B Mettauer; B Geny; J Lonsdorfer Journal: Eur J Appl Physiol Date: 2000-07 Impact factor: 3.078
Authors: R Lodi; J M Cooper; J L Bradley; D Manners; P Styles; D J Taylor; A H Schapira Journal: Proc Natl Acad Sci U S A Date: 1999-09-28 Impact factor: 11.205
Authors: R Lodi; B Rajagopalan; A M Blamire; J M Cooper; C H Davies; J L Bradley; P Styles; A H Schapira Journal: Cardiovasc Res Date: 2001-10 Impact factor: 10.787
Authors: David R Lynch; Gwen Lech; Jennifer M Farmer; Laura J Balcer; William Bank; Britton Chance; Robert B Wilson Journal: Muscle Nerve Date: 2002-05 Impact factor: 3.217
Authors: Bart Drinkard; Mary D Roberts; Lisa M Ranzenhofer; Joan C Han; Lisa B Yanoff; Deborah P Merke; David M Savastano; Sheila Brady; Jack A Yanovski Journal: Med Sci Sports Exerc Date: 2007-10 Impact factor: 5.411
Authors: Gayatri Maria Schur; Julia Dunn; Sara Nguyen; Anna Dedio; Kristin Wade; Jaclyn Tamaroff; Nithya Mitta; Neil Wilson; Ravinder Reddy; David R Lynch; Shana E McCormack Journal: J Neurol Date: 2021-10-15 Impact factor: 6.682
Authors: Yi Na Dong; Clementina Mesaros; Peining Xu; Elizabeth Mercado-Ayón; Sarah Halawani; Lucie Vanessa Ngaba; Nathan Warren; Patrick Sleiman; Layne N Rodden; Kimberly A Schadt; Ian A Blair; David R Lynch Journal: PNAS Nexus Date: 2022-07-26